Clinical Trial Update: Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update compares rimonabant at 5 mg/day and 20 mg/day with placebo for smoking cessation. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Smoking Cessation | Phase 3 | Status: COMPLETED